TIME Is Looking For the World's Top HealthTech Companies of 2026

Why It Matters

The ranking provides a high‑profile endorsement that can attract investment, partnerships, and talent, while signaling broader industry momentum toward digital and sustainable health solutions.

Key Takeaways

• TIME partners with Statista for 2026 health‑tech ranking
• Application deadline June 14, 2026; results in September
• Open to digital health, telemedicine, AI diagnostics, devices
• Emphasizes innovation, accessibility, sustainability in healthcare
• Inclusion boosts visibility, funding, and market credibility

Pulse Analysis

The health‑technology sector is on a rapid growth trajectory, with global spending projected to exceed $600 billion by 2027. Advances in artificial intelligence, remote monitoring, and interoperable data platforms are reshaping patient care, driving cost efficiencies, and expanding access in underserved markets. As hospitals and insurers scramble to integrate these tools, third‑party validation becomes a critical differentiator for emerging firms seeking to stand out in a crowded landscape.

TIME’s upcoming World’s Top HealthTech Companies list, produced in collaboration with Statista, adds a reputable, media‑driven layer of credibility to the competitive arena. The ranking will consider companies across digital health apps, telemedicine services, AI‑based diagnostic engines, smart medical devices, and health‑data analytics platforms. Applicants must submit detailed information by June 14, 2026, but selection will be merit‑based, focusing on demonstrable impact on innovation, accessibility, and sustainability. Statista’s data expertise is expected to underpin a rigorous, data‑centric evaluation process.

For health‑tech startups and scale‑ups, earning a spot on the TIME list can translate into heightened investor interest, strategic partnership opportunities, and amplified brand awareness. The endorsement often serves as a signal to venture capitalists and corporate acquirers that a company has achieved a level of market validation beyond typical pitch decks. As the industry continues to converge on value‑based care and patient‑centric models, such recognitions will likely influence capital flows and accelerate the adoption of next‑generation health solutions.